Navigation Links
CDC Recommends Shingles Vaccine for Those Over 60

ZOSTAVAX could prevent two thirds of shingles cases, expert says

THURSDAY, May 15 (HealthDay News) -- All adults aged 60 and older should be vaccinated against shingles, a condition that can cause debilitating chronic pain, the U.S. Centers for Disease Control and Prevention recommended on Thursday.

This new recommendation replaces the agency's provisional recommendation, made in 2006, after the ZOSTAVAX vaccine was approved by the U.S. Food and Drug Administration.

"The publication of these guidelines will give an impetus to the use of shingles vaccine," said Dr. William Schaffner, chairman of the Department of Preventive Medicine and a professor in the Division of Infectious Diseases at Vanderbilt University School of Medicine and vice president of the National Foundation for Infectious Diseases.

In addition, it may get health insurance companies to start covering the cost of the vaccine, Schaffner said. "Also, it will give physicians some stimulus to use this vaccine more extensively than they have to date," he said.

The new recommendation was published in the May 15 online edition of the Mortality and Morbidity Weekly Report.

Schaffner thinks getting vaccinated is very important. "There are about 1 million cases of shingles that occur each year in the United States," he said. "Half of these occur in people aged 60 and older."

Moreover, 50 percent of those who live to 85 will have shingles, Schaffner said. "Shingles is very common and ranges from mild to very severe and disabling," he said.

However, people who have an immunodeficiency disease should not be vaccinated, Schaffner added.

In evaluating the vaccine, known as ZOSTAVAX and manufactured by Merck & Co., researchers found that for those aged 60 and older, the vaccine reduced the occurrence of shingles by about 50 percent. For those aged 60 to 69 years old, the vaccine reduced the occurrence of shingles by 64 percent.

"The vaccine is about two-thirds effective," Schaffner said. "It will prevent about two-thirds of the cases of shingles and its consequent pain syndrome. Like most vaccines, it's not perfect, but it offers the promise of reducing the risk and occurrence of shingles by two-thirds, and that's not bad."

One drawback to the vaccine is its cost, which is about $150, Schaffner noted. In addition, the vaccine may not be covered by private insurance. For Medicare patients, it is currently covered under the Part D drug benefit, so its cost will vary by provider.

Schaffner hopes that the new CDC recommendation will make the vaccine more available.

Shingles is caused by the chickenpox virus, known as varicella zoster, which remains dormant in the body after being infected. Shingles causes blisters, which develop on one side of the body, including the face, and can cause severe pain that can last for weeks, months or years.

One potential consequence of shingles, if it appears on the face, is loss of some vision or blindness, should the virus infect the eye, Schaffner noted. Shingles can also result in hearing loss.

While mild cases of shingles usually disappear within a few weeks, severe cases can cause pain that lasts for years. This long-term nerve pain, called post herpetic neuralgia, is described as burning, stabbing, throbbing or shooting pain.

More information

For more information on shingles vaccine, visit the U.S. Centers for Disease Control and Prevention.

SOURCES: William Schaffner, M.D., professor and chairman, Department of Preventive Medicine, professor, Division of Infectious Diseases, Vanderbilt University School of Medicine, and vice president, National Foundation for Infectious Diseases; May 15, 2008, Morbidity and Mortality Weekly Report, early edition

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. National Council on Disability Recommends Improving Federal Data Describing the Status of Americans with Disabilities
2. American Cancer Society Recommends Virtual Colonoscopy
3. Task Force Recommends Against Screening for Chronic Obstructive Pulmonary Disease Using Spirometry
4. CDC Vaccine Committee Recommends More Shots for Children
5. FDA Advisory Committee Recommends US Approval of Rotavirus Vaccine
6. Senate Finance Committee Recommends Ways That Medicare Can Enhance Current Physician Quality Reporting Initiative (PQRI)
7. FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation
8. Datascope Recommends Shareholders Re-Elect its Two Incumbent Directors and Reject Ramius Opposition Slate
9. FDA Advisory Committee Recommends Approval of Abbotts XIENCE(TM) V Drug Eluting Stent System
10. National Association of EMS Educators (NAEMSE) Recommends Screening for Carbon Monoxide Poisoning
11. AHRQ Report Recommends Use of Existing Call Centers to Expand Communications in Public Health Emergencies
Post Your Comments:
Related Image:
CDC Recommends Shingles Vaccine for Those Over 60
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind challenges ... health and wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular ... experienced by parents and bring advice from parenting experts within their reach. As ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... workshops to discuss bioavailability and the need to integrate dose form selection in ... collaboration with OBN, the membership organization supporting and bringing together the UK’s emerging ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 ... aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie voor ... ) --> ... ) Uit ... Centrum (LUMC) blijkt ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Japanese therapeutic drug monitoring market, including emerging tests, ...
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda SyMRI ... (MR-bilder) för patienter med multipel skleros ... forskningsavtal med SyntheticMR AB för att kunna ... på sjukhuset. Med SyMRI kan man generera ...
Breaking Medicine Technology: